Scientific Organization:
Dr. Gerassimos J. Mantzaris, Athens
Prof. Dr. Dr. Gerhard Rogler, Zürich
Prof. Dr. Axel Dignass, Frankfurt
Program
Welcome
G.J. Mantzaris, Athens; G. Rogler, Zurich
Session I – From Bench to Bedside
Chair: G.J. Mantzaris, Athens; G. Rogler, Zurich
New immunological pathways in IBD
G. Rogler, Zurich
Discussion
New treatment targets
D. Turner, Jerusalem
Discussion
Session II – Update of IBD treatment
Chair: G.J. Mantzaris, Athens; G. Rogler, Zurich
Selecting the 1st line biologic
S. Ghosh, Birmingham
Discussion
What is new in IBD surgery?
W.A. Bemelman, Amsterdam
Discussion
Session III – Covid-19 interactive discussions beyond borders
Chair: A. Dignass, Frankfurt; G.J. Mantzaris, Athens
Lessons from IBD and other disciplines
Dermatology
D. Thaçi, Lübeck
Rheumatology
D. Vassilopoulos, Athens
Gastroenterology
R. Ungaro, New York
The Greek Gastro Covid-19 experience
G. Bamias, Athens
Interactive panel discussion
Closing Remarks
G.J. Mantzaris, Athens
A. Dignass, Frankfurt
Scientific Organization:
Prof. Dr. Jesús K. Yamamoto-Furusho, Mexico City
Program
Welcome
J.K. Yamamoto-Furusho,
Chair: F. Gomollón, Zaragoza; J.K. Yamamoto-Furusho, Mexico City
Epidemiological and clinical aspects of SARS-CoV-2 infection in IBD patients
J.K. Yamamoto-Furusho, Mexico City
Discussion
What is the role of 5-aminosalicylates (5-ASA) in the management of patients with IBD in the pandemic era?
F. Gomollón, Zaragoza
Discussion
The impact of the use of local and systemic steroids in the clinical course of IBD patients in the Covid-19 era
R. Panaccione, Calgary
Discussion
What is the clinical impact in the use of immunomodulators in patients with IBD and SARS-CoV-2 infection and Covid-19?
S. Ghosh, Birmingham
Discussion
Therapy with vedolizumab in the times of Covid-19
S. Schreiber, Kiel
Discussion
Is ustekinumab safe in the treatment of IBD patients with SARS-CoV-2 infection or Covid-19?
R. Ungaro, New York
Discussion
What is the recommendation about the use of tofacitinib in UC patients with SARS-CoV-2 infection or Covid-19?
W.J. Sandborn, San Diego
Discussion
Closing remarks
J.K. Yamamoto-Furusho, Mexico City